Key result
Cryo-EM structures of human NaV channels reveal isoform-specific pockets for precision therapeutics.
Why the study?
Subtle structural divergences across the nine human voltage-gated sodium channel isoforms underlie distinct tissue distributions, biophysical properties, and disease susceptibilities ranging from cardiac arrhythmias to neurological and muscular channelopathies. Recent cryo-electron microscopy and computational advances needed to be integrated into a mechanistic model connecting channel architecture to gating, disease, and isoform-selective drug design.
This review synthesizes recent cryo-electron microscopy and structural biology breakthroughs regarding human voltage-gated sodium (NaV) channels, linking channel architecture to gating mechanisms, channelopathies such as cardiac arrhythmias, and the rational design of isoform-selective therapies.
Voltage-gated sodium (NaV) channels are critical transmembrane proteins responsible for the initiation and propagation of electrical signals in excitable tissues. They consist of a large α subunit and auxiliary β subunits. Together, the voltage sensing, ion selectivity, and rapid gating transitions regulate neuronal, muscular, and cardiac excitability. Recent cryo-electron microscopy breakthroughs have transformed the understanding of NaV structure–function relationships, revealing the asymmetric organization of voltage-sensing domains (VSD), the architecture of the DEKA selectivity filter, the mechanical coupling between S4–S5 linkers and S6 gating helices, and the allosteric mechanism by which the IFMT motif mediates fast inactivation. Across the nine human NaV isoforms, subtle structural divergences underlie distinct tissue distributions, biophysical properties, and disease susceptibilities, explaining the diverse channelopathies that range from epilepsy and cardiac arrhythmias to skeletal muscle disorders and painful neuropathies. These high-resolution structures also illuminate isoform-specific pharmacological pockets, including membrane-dependent cavities in VSD4 and dynamic fenestrations that govern state-dependent drug access, enabling the rational design of small molecules, peptide toxins, and hybrid therapeutics with improved selectivity. Advances in structural biology, biochemistry, and computation have established an integrated mechanistic model that connects NaV channel architecture to gating, inactivation, isoform-specific function, and human disease. This growing molecular atlas now supports next-generation precision therapies aimed at selectively modulating NaV channel activity in neurological, muscular, cardiac, and pain disorders.
No takes yet. Share an insight, caveat, or question.
Boazinha et al. (2026) conducted a review in Channelopathies (epilepsy, cardiac arrhythmias, skeletal muscle disorders, painful neuropathies). Cryo-electron microscopy breakthroughs across the 9 human NaV channel isoforms reveal key structure-function mechanisms and isoform-specific pharmacological pockets for precision therapies.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from Pharmacological Research